The stability of the Wnt pathway transcription factor beta-catenin is tightly regulated by the multi-subunit destruction complex. Deregulated Wnt pathway activity has been implicated in many cancers, making this pathway an attractive target for anticancer therapies. However, the development of targeted Wnt pathway inhibitors has been hampered by the limited number of pathway components that are amenable to small molecule inhibition. Here, we used a chemical genetic screen to identify a small molecule, XAV939, which selectively inhibits beta-catenin-mediated transcription. XAV939 stimulates beta-catenin degradation by stabilizing axin, the concentration-limiting component of the destruction complex. Using a quantitative chemical proteomic approach, we discovered that XAV939 stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, our study provides new mechanistic insights into the regulation of axin protein homeostasis and presents new avenues for targeted Wnt pathway therapies.

The non-receptor protein tyrosine phosphatase SHP2, encoded by PTPN11, has an important role in signal transduction downstream of growth factor receptor signalling and was the first reported oncogenic tyrosine phosphatase. Activating mutations of SHP2 have been associated with developmental pathologies such as Noonan syndrome and are found in multiple cancer types, including leukaemia, lung and breast cancer and neuroblastoma. SHP2 is ubiquitously expressed and regulates cell survival and proliferation primarily through activation of the RAS–ERK signalling pathway. It is also a key mediator of the programmed cell death 1 (PD-1) and B- and T-lymphocyte attenuator (BTLA) immune checkpoint pathways. Reduction of SHP2 activity suppresses tumour cell growth and is a potential target of cancer therapy. Here we report the discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHP2 in an auto-inhibited conformation. SHP099 concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumour xenograft models. Together, these data demonstrate that pharmacological inhibition of SHP2 is a valid therapeutic approach for the treatment of cancers.

Two decades have passed since the rule of five ushered in the concept of "drug-like" properties. Attempts to quantify, correlate, and categorize molecules based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines. Examination of oral drug parameters approved before and after the original Ro5 analysis demonstrates that some parameters such as clogP and HBD remained constant while the cutoffs for parameters such as molecular weight and HBA have increased substantially over the past 20 years. The time dependent increase in the molecular weight of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that molecular weight is a "drug-like" property. This analysis does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.

Dopamine forms an initial structure coordinated to the surface of the iron oxide nanoparticle as a result of improved orbital overlap of the five-membered ring and a reduced steric environment of the iron complex. However, through transfer of electrons to the iron cations on the surface and rearrangement of the oxidized dopamine, a semiquinone is formed. Because of free protons in the system, oxygens on the surface are protonated, which allows for the Fe2+ to be released into the solution as a hydroxide. This released fragment of the nanoparticle will then eventually oxidize in air to a form of an iron(III) oxyhydroxide. All of the reported results demonstrate that the reactivity between Fe3+ and dopamine quickly facilitates the degradation of the nanoparticles. The energetic modeling studies substantiate our proposed decomposition mechanism and thus conclude that the use of dopamine as a robust anchor for iron oxide or iron oxide shell particles will not fulfill the need for stable ferrofluids in most biomedical applications.

This paper discusses the relationship between synthesis conditions, crystal morphology, and theoretical modeling of copper and nickel nanoparticles prepared by a modified polyol process. The polyol serves as a solvent, a reducing agent, and a capping agent, and we investigate the role several polyol types play in the nucleation and growth of metallic nanoparticles. The nanoparticles are characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), and X-ray photoelectron spectroscopy (XPS). Our results demonstrate that changing the solvent system from a short chain polyol (ethylene glycol) to a long chain polyol (tetraethylene glycol) greatly affects the resulting morphology of copper nanoparticles. These results suggest that the polyol is playing a major role as an in situ capping agent and that the various polyol chain lengths in-turn result in various particle morphologies by directly altering the nucleation and growth steps. We were also able to use theoretical modeling to investigate the mechanism for growth to better understand the intermediate structure stability. This work presents an alternative approach in investigating the polyol mechanism by using both theoretical and experimental results and opens new insight for the synthesis of metals and alloys by the polyol process.